sigmoidoscopy or colonoscopy, abdominal ultrasound scan and computed tomography (or, when available, magnetic resonance imaging) scan of the abdomen [4] . Besides blood and stool testing, the diagnostic work-up thus entails techniques and procedures that are variably invasive (e.g. sigmoidoscopy, colonoscopy, biopsy), or which may be associated with substantial future health risks (e.g. those attributable to radiation exposure). The introduction of reliable and accurate laboratory tests that would contribute to limit the number of unnecessary further investigations should hence be regarded as a foremost perspective for safeguarding patients health and lowering healthcare expenditures. These considerations are even more relevant for IBD patients monitoring.
Among the various (noninvasive) biomarkers that have been proposed over the past few years, fecal calprotectin has gained a prominent role. A meta-analysis of eight studies totaling 1062 subjects recently concluded that a patient with a fecal calprotectin value ≤ 40 μg/g has a 1% probability of having IBD and a 84.1% probability of being healthy [5] , thus exhibiting better diagnostic performance than C-reactive protein, erythrocyte sedimentation rate and fecal lactoferrin for ruling out this condition. Despite some analytical and preanalytical drawbacks remain [6] [7] [8] [9] , encouraging data has also been recently published about the clinical efficacy of this biomarker for monitoring disease activity, response to treatment and relapse [10, 11] .
In this issue of Clinical Chemistry and Laboratory Medicine, Dumoulin et al. [12] describe the results of an interesting study about the measurement of leukocyte esterase activity in fecal extracts. The analytical performance of the technique was adequate for routine diagnostics, and the correlation with fecal calprotectin was found to be acceptable. Some advantages over fecal calprotectin testing were also emphasized, namely a higher sensitivity and a lower vulnerability against proteolysis, two aspects that seemingly make leukocyte esterase a highly stable, reliable and more affordable biomarker for diagnosis and monitoring of IDB.
Although further studies are needed to translate these preliminary results into clinical practice, it seems reasonable to hypothesize that prime time for noninvasive biomarkers of IBD may not be too late.
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